Zyomyx issued five new biotech patents

NewsGuard 100/100 Score

Zyomyx a privately held biotechnology company, has announced that the United States Patent and Trademark Office issued five new patents to the Company. With these additions, Zyomyx has further strengthened its proprietary position in the area of protein biochip technology development and commercialization.

Zyomyx has built a United States and international patent estate that includes over 90 patents and pending patent applications. Together with rights to patents licensed by others, Zyomyx owns or has exclusive rights to more than 120 United States and international patents and patent applications. The five new patents include: U.S. Patent 6,730,516, entitled "Microfluidic Devices and Methods"; U.S. Patent 6,720,165, entitled "Methods for Making Antibody Fragments and Compositions Resulting Therefrom"; U.S. Patent 6,720,157, entitled "Chips Having Elevated Sample Surfaces"; U.S. Patent 6,186,154, entitled, "Screening of Phage Displayed Peptides without Clearing of Cell Culture"; and U.S. Patent 6,682,942, entitled, "Microdevices for Screening Biomolecules".

"The recognition by the United States Patent and Trademark Office in granting these five patents, as well as the numerous other U.S. patents that have been granted or allowed, is exciting for Zyomyx as we continue our pioneering efforts in the commercialization of protein biochip technologies in anticipation of our customers' current and future research needs," said Robert Monaghan, Zyomyx' President and Chief Executive Officer.

The Company has a strong intellectual property position in protein biochips and in other related micro-scale protein analytical methodologies. Since its founding in 1998, Zyomyx has pursued an aggressive intellectual property strategy aimed at creating substantial barriers for other companies in the protein biochip business and also at providing appropriate freedom to operate in the development and application of its core proteomics and nanofluidic technologies.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered method predicts protein dynamics to accelerate drug discovery